The effect of bretylium on ventricular tachycardia induced by digitalis was studied in Dialurethane-anesthetized cats with continuous monitoring of the electrocardiogram and arterial blood pressure. Ventricular tachycardia was produced by repeated injections of deslanoside (25 ,g/kg) at 15 min intervals. Only one of eight animals showed conversion of ventricular tachycardia to sinus rhythm with bretylium administration (2-100 mg/kg i.v.). In each animal, bretylium increased the ventricular rate. The effect of bretylium (30 mg/kg i.v.) on duration of ventricular tachycardia induced by deslanoside (0.75 ,ug/kg/min) was also studied. Duration was shortened from 65 + 8.0 min to 7 1.0 min, but the reduction was due to the intervention of either ventricular fibrillation or severe hypotension caused by bretylium. Pretreatment with propranolol (0.5 mg/kg i.v.) prevented these deleterious effects and unmasked an antiarrhythmic effect of bretylium since duration of ventricular tachycardia was significantly shorter (40 6.0 min) than the controls (65 + 8.0 min). In addition, an antiarrhythmic effect of bretylium was noted when it was administered as a dose of 30 mg/kg ip to animals 24 and 4 hours prior to deslanoside intoxication; 231 ,ug/kg deslanoside were now required for inducing ventricular tachycardia as compared to 175 ,ug/kg deslanoside in controls. Thus, bretylium given alone during a digitalis-induced ventricular tachycardia increases both the rate of ventricular tachycardia and the likelihood of ventricular fibrillation. These deterious effects appear to be related to a norepinephrine-releasing action and may be avoided by either pretreatment with propranolol or administration of bretylium several hours prior to digitalis intoxication.
SEVERAL LINES of evidence have appeared in the recent literature to indicate that the sympathetic nervous system plays an important role in the development of digitalis-induced ventricular arrhythmias. First, a positive correlation exists between the development of serious ventricular rhythm disorders produced by digitalis and excitation of the sympathetic nervous system produced by digitalis." 2 Second, arrhythmias can be precipitated by either sympathetic nerve stimulation or administration of isoproterenol and norepinephrine in animals exposed to subarrhythmic doses of digital-iS.3, 4Third, surgical interruption of sympathetic cardiac pathways protects the heart from otherwise cardiotoxic doses of digitalis.5 8 Fourth, conversion of digitalis-induced arrhythmias by drugs correlates with depression of digitalis-induced sympathetic neural hyperactivity." 2, 910 Fifth, drugs which normally counter digitalis arrhythmias fail to do so when the heart is deprived of sympathetic influence." 1 12 In view of the above observations we would anticipate that bretylium, a drug recommended as an important agent for the therapy of cardiac arrhythmias, would act as a "double edge sword" in the presence of ventricular arrhythmias produced by digitalis. We take this view because bretylium possesses opposing actions on the adrenergic nervous system. On the one hand, it exerts an antiadrenergic action by interfering with norepinephrine release from postganglionic sympathetic nerve endings. 13 On the other hand, it releases norepinephrine from adrenergic nerve terminals,'4' 15 and potentiates the effect of circulating catecholamines on adrenergic receptors.15 ' 16 Circulation, Volume XLVII, May 1973 Propranolol The purpose of our present study was to determine whether bretylium would exert a beneficial or harmful influence, or both, on ventricular arrhythmias induced by digitalis.
Methods
Cats of either sex with weights ranging from 1.6 to 3.2 kg were anesthetized with 0.6 ml Dial-urethane (Ciba) per kg administered by the intraperitoneal route. Tracheal cannulation was performed but all animals were allowed to breathe spontaneously. Polyethylene catheters were inserted into the femoral artery and vein for the purpose of measuring arterial blood pressure and administering drugs, respectively. The animal's body temperature was maintained between 36.50 and 38.5°C by warming with an infrared lamp. The electrocardiogram (lead II) and the arterial pressure were continuously recorded on a Beckman RB recorder.
Three types of experiments were performed to evaluate the effects of bretylium: Type 1. Deslanoside was administered in a dose of 25 ,ug/kg i.v. every 15 min to produce ventricular tachycardia. The criteria for ventricular tachycardia was a sustained idioventricular rhythm lasting at least 1 min and characterized by the presence of independent nonconducted atrial activity. After 1 min of ventricular tachycardia, bretylium was administered intravenously to test its capacity to convert deslanoside-induced ventricular tachycardia to sinus rhythm. Type II. Deslanoside was infused at a constant continuous rate of 0.75 ,gg/kg/min until ventricular tachycardia of 3-min duration occurred. Digitalis infusion was terminated and bretylium, 30 mg/kg i.v., was administered to test its capacity to shorten the duration of an established ventricular tachycardia. Type III. Deslanoside was administered as in the experiments of type I for the purpose of determining doses of deslanoside required to produce ventricular tachycardia and ventricular fibrillation in control animals and animals pretreated with bretylium (30 mg/kg i.v.) 24 and 4 hours prior to deslanoside intoxication. the cumulative effects of 25 1ag/kg deslanoside administered at 15 min intervals. Results obtained are summarized in table 1. Only one animal was converted from ventricular tachycardia to a regular sinus rhythm. The other seven animals stayed in ventricular tachycardia and developed more serious rhythm changes with increasing doses of bretylium ( fig. 1 ). Low doses of the drug (2-5 mg/kg) significantly increased the rate of the ventricular rhythm. The magnitude of the increase was 25.7 + 6.7 beats/mim. Higher doses (6-100 mg/kg) produced ventricular fibrillation in two animals anid severe hypotension in five animals. The one animal A LWL N, 'Qr C that did convert to sinus rhythm did so because bretylium produced an "overdrive suppression" of abnormal pacemaker activity. That is, prior to bretylium administrationi, the rate of the ventricular tachycardia was 170 beats/min; after conversion with 3 mg/kg of bretylium, the reestablished sinus rate was 220 beats/min. Conversion lasted about 1.5 min. Additional bretylium (total dose of 47 mg/kg) resulted in ventricular fibrillation ( fig. 2 ). It was apparent from the above series of experiments that bretylium was generally ineffec- antiarrhythmic drugs such as diphenylhydantoin,ti diphenylthiohydantoin,'8 propranololi 2 and clonidine'0 showed that conversion of this rhythm disturbance to a normal sinus rhythm with a sinus rate less than the ventricular rate readily occurred when these drugs were adminstered. An explanation for the negative results obtained with bretylium in the arrhythmogenic model employed is that time is required for its antiarrhythmic action to develop. To test this possibility a slow, continuous infusion of deslanoside was used to produce the arrhythmia. Once the arrhythmia was established the infusion was stopped (after 3 min of ventricular tachycardia. The remaining four animals never reverted to sinus rhythm; instead three fibrillated and one died from hypotension. The average duration of the arrhythmia when the data from all nine animals are grouped together was 72.0 ± 14.1 min. No antiarrhythmic effect of bretylium was noted when administered to seven additional animals intoxicated with deslanoside. In fact, all animals died within 11.0 min from the time that bretylium was given. The average duration of ventricuar tachycardia was 7.07 ± 1.05 min. It must be emphasized that the significant reduction in time which animals spent in abnormal cardiac rhythm as compared to control does not represent an antiarrhythmic effect of bretylium but, instead, represents a deleterious effect of the drug when administered to animals with a digitalis-induced ventricular tachycardia. Four of the seven animals fibrillated while the remaining three died from hypotension. Before these terminating events occurred, bretylium produced a significant decrease in arterial pressure and an increase in ventricular rate; the latter change was not statistically significant (table 2). A representative experiment illustrating the effects of 30 mg/kg of bretylium administered during the deslanoside-induced ventricular tachycardia is shown as figure 3 .
Another six animals that were to be given bretylium were first pretreated with propranolol (0.5 mg/kg). The propranolol was administered while the animals were still in sinus rhythm (i.e., after a dose of 112.5 ,ug/kg deslanoside had been infused) and produced a significant decrease in heart rate (table 2) . Beta-adrenergic blockade prevented the deleterious effects of bretylium and unmasked an antiarrhythmic effect of the drug. Four of the six animals recovered from the arrhythmia since normal sinus rhythm was reestablished 40.0 + 6.0 min after the onset of ventricular tachycardia. The remaining two animals never reverted to sinus rhythm but died from hypotension. The duration of time spent in ventricular tachycardia was significantly less (P < 0.05) for the propranolol-pretreated animals treated with bretylium than for the control animals (65.2 + 8.0 min). A representative propranolol-pretreatment experiment illustrating the effects of 30 mg/kg of bretylium administered during the deslanoside-induced tachycardia is shown as figure 4 .
Propranolol pretreatment alone did not significantly influence the duration of time spent in ventricular tachycardia. The ECGs of four of the six animals studied showed sinus rhythm at 74.0 14.5 min after ventricular tachycardia had been initiated. The remaining two animals did not spontaneously convert; one animal fibrillated and the other animal was terminated after exhibiting a ventricular arrhythmia for 6 hours. Pretreatment of animals with 30 mg/kg bretylium 24 and 4 hours prior to intoxicating them with deslanoside significantly increased the dose of deslanoside necessary to produce ventricular tachycardia (table 3) . Pretreatment with bretylium also circulation, Volume XLVIIJ, May 1973 influenced the base blood pressure and heart rate as well as the effect of deslanoside on heart rate. After bretylium, cats had significantly lower heart rates and pressures to start with, and the usual bradycardia noted with deslanoside in control animals did not occur (table 3) .
Discussion
The results of our study indicate that the antiarrhythmic drug, bretylium, may actually be arrhythmogenic if administered to cats with a ventricular tachycardia caused by digitalis. When increasing doses of bretylium were given for the purpose of converting ventricular tachycardia to sinus rhythm, it increased the rate of the ventricular tachycardia, and in two cases, produced ventricular fibrillation. When a fixed dose of bretylium was given for the purpose of shortening the duration of an established ventricular tachycardia, it caused death in all animals tested. No animal survived more than 11 min after bretylium was administered while animals treated in the same way with digitalis but not given bretylium survived for an average of 72 min with eventual return to sinus rhythm occurring in more than half of the animals studied.
There have been three other reports which indicate that bretylium may be arrhythmogenic in the presence of digitalis. The two most impressive studies represent preliminary data. In the first, dogs intoxicated with ouabain were given bretylium (5 mg/kg i.v.), and in each case, bretylium increased the ventricular rate. In no instance did conversion to sinus rhythm occur.'!9 In the second, dogs intoxicated with acetylstrophanthidin to an endpoint of ventricular tachycardia were allowed 5 min i.e., studies where bretylium was given to animals c;-D | tx I°not previously treated with digitalis, the results are 0 WQ + _ v _ *<°> consistent with our finding that the heart exposed to A < .=: 1l digitalis may be adversely affected by giving it bretylium.
o fi o .e The mechanism for the adverse effect of bretylitb < -H > s v s s; :3 um seen in hearts previously exposed to toxic doses of digitalis has been postulated as being due to its to°s ympathomimetic effect. force,25 and decrease in ventricular escape time22 occur immediately and become maximum in about 10 min after injection. Consistent with the postulate that bretylium-induced arrhythmogenesis is due to indirectly released norepinephrine is the fact that norepinephrine has the capacity to produce ventricular arrhythmias. 26 In this regard, it has been reported by several investigators that catecholamines increase the sensitivity of the heart muscle to the toxic action of digitalis drugs. 3 4, 26 27 Conversely, digitalization increases the sensitivity of the heart muscle to the arrhythmogenic effect of catecholamines. 27 Finally, either depletion of cardiac catecholamines with reserpine or blockade of beta-adrenergic receptors with propranolol prevents the positive chronotropic and inotropic effects of bretylium.24, 25 Based on the above findings, we felt that pretreatment with propranolol might protect the heart from the deleterious effects of bretylium. This was indeed the case since four of the six animals tested reverted from ventricular tachycardia to sinus rhythm after bretylium administration. Without propranolol pretreatment, six of six animals tested died within 11 min after bretylium administration. In summary, the arrhythmogenic effect of bretylium can be attributed to its indirect action of releasing endogenous catecholamines since the time-action curves for both effects are closely matched and blockade of the cardiac effects of released norepinephrine largely prevents arrhythmogenesis.
In addition to its sympathomimetic effects, bretylium blocks the release of endogenous norepinephrine by the nerve-action potential. The timeaction curve for this effect is different than for the sympathomimetic effect. According to Kirpekar and Furchgott,1,5 partial blockade of the positive inotropic response resulting from sympathetic nerve stimulation occurs 15 min after drug administration with complete blockade occurring 45 min after drug administration. Similarly, Gilmore and Siegel23 have shown that the increases in coronary venous catecholamine output normally produced by sympathetic nerve stimulation do not occur 20 min after drug administration. Thus, the norepinephrinereleasing effect occurs early (immediately after injection) while the blockade of norepinephrine release occurs late (15-20 min after injection).
Since the sympathetic nervous system plays an important contributory role in the development of digitalis-induced ventricular arrhythmias, blockade of norepinephrine release by bretylium should help to counteract these arrhythmias. This was indeed the case since our results show that bretylium significantly shortened the duration of an established ventricular tachycardia of animals in which the early sympathomimetic effect of bretylium had been prevented by pretreatment with propranolol. Duration of ventricular tachycardia was 40±1 6.0 min as compared to 65 + 8.0 min for controls. The time period over which the antiarrhythmic effect was noted is consistent with the time period over which the blockade of norepinephrine release occurs. The possibility exists that the earlier return to sinus rhythm was not due to bretylium but was due to pretreatment with propranolol. To test this possibility, six animals pretreated with propranolol but not given bretylium were studied. Results obtained showed restoration to sinus rhythm 74 min after ventricular tachycardia was initiated. The time required was not significantly different than the time required for the controls but was significantly longer than the time required for the propranololpretreated animals treated with bretylium. Thus, the antiarrhythmic effect noted in the latter group was due to the bretylium and not to the propranolol.
To test further the influence of bretylium-induced sympathetic neurodepression on digitalis toxicity without exposing the digitalized heart to the initial period of bretylium-induced sympathomimetic effects, we administered bretylium alone to animals 24 and 4 hours prior to intoxicating them with deslanoside and determined the doses required for producing ventricular tachycardia. An antiarrhythmic effect was noted as a significantly larger dose of deslanoside was needed for inducing ventricular tachycardia as compared to controls. Similar results have been obtained by Papp and Vaughan
Williams.21
Our assumption that the antiarrhythmic mechanism of action of bretylium is due to its ability to block release of norepinephrine from cardiac sympathetic nerves agrees with the conclusions of Bassett and Hoffman. 28 In their review of antiarrhythmic drugs, they state that "bretylium does not resemble either the quinidinelike drugs or DPH (diphenylhydantoin) and lidocaine in its effect on the relative magnitude of changes in effective refractory period and action potential duration. This fact, plus the failure of bretylium to decrease automaticity suggests that its antiarrhythmic efficacy in laboratory studies is not due to any intrinsic direct electrophysiologic effects." Its antiarrhythmic action may be exerted "through depression of neural function." In a larger sense, evidence exists to support the view that bretylium, as well as other antiarrhythmic drugs, (e.g. diphenylhydantoin and propranolol) exert some of their antiarrhythmic effects through depression of neural function.", 2, 9, 29, 30 In summary, our experiments demonstrate that bretylium has both arrhythmogenic and antiarrhythmic properties and both properties appear to be related to its effect on the sympathetic nervous system. This knowledge may be helpful in defining the role of bretylium in the therapy and prevention of cardiac arrhythmias. In the case of therapy for ventricular arrhythmias caused by digitalis, bretylium should be avoided especially by the intravenous route since worsening of the arrhythmia occurs.
